The functions and effects of Venetoclax

Venetoclax (Venetoclax) is effective in both CLL (chronic lymphocytic leukemia) and AML (acute myeloid leukemia), and trials report that significantly more patients achieved complete remission using venetoclax in combination with other therapies compared with standard therapy. Venetoclax also works quickly, with many people taking an average of a month to feel a slowdown in disease progression.

For chronic lymphocytic leukemia, a large proportion of patients respond to venetoclax after other treatments have failed or are inappropriate; when combined with rituximab, venetoclax extends patients' survival without worsening their disease. This study of patients with previously untreated CLL shows that venetoclax plus obinutuzumab is a reasonable treatment option. This combination offers the possibility of avoiding the side effects of chemotherapy drugs. For acute myeloid leukemia, venetoclax extends the survival time of patients taking azacitidine. Because decitabine is a drug with similar properties to azacitidine, decitabine may have similar benefits.

The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).